Novo Nordisk's Move for Metsera Looks Defensive -- Market Talk
Dow Jones
Oct 31
1349 GMT - Novo Nordisk's effort to usurp Pfizer's bid for Metsera looks a very defensive move, Deutsche Bank analysts Emmanuel Papadakis and Henrietta Boeg write. The $9 billion bid was thoroughly unexpected and the bank questions what it implies for Novo Nordisk's confidence in its own obesity programs. It also seems unlikely that the move is unrelated to recent board changes, Deutsche Bank adds. The bank has a buy rating and 600 Danish kroner target price for the stock. Shares fall 2.7% to 314 kroner. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
October 31, 2025 09:49 ET (13:49 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.